Home > PS Ratio > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
PS (Price/Sales) Ratio

The Current P/S Ratio of GLENMARK PHARMACEUTICALS is 3.10.

Share Price ₹1,443.3May 14,2025
Market Cap ₹40,729.9 Cr
Sales-TTM₹13,128.5 CrTTM-Consolidated Results
Price/Sales3.10xCalculated as Market Cap/Sales
Explore Stock Analytics
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results

Definition & Calculation of PS (Price/Sales) ratio of GLENMARK PHARMACEUTICALS

Price-to-Sales ratio, P/S Multiple, or P/S Ratio is an important valuation multiple that is defined as:

P/S = Market Capitalization / Sales

or, using per-share numbers:

P/S = Stock Price / Sales Per Share

Applying the above formula, P/S ratio of GLENMARK PHARMACEUTICALS is calculated as :

Current Market Cap [ ₹40,729.9 Cr] as on May 14,2025

(/) Sales [ ₹13,128.5 Cr] based on TTM-Consolidated Results

(=) P/S Ratio [ 3.10x ]

P/S Ratio indicates 'the multiple of sales' investors are willing to pay to own one share of the company.

Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay '3.10 times sales' to own 1 share of the company.

PS Multiples are one of the most widely used valuation multiple in the industry.

P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.

You may also explore Price to Earnings ratio or Price to Book ratio of GLENMARK PHARMACEUTICALS !

The chart below summarizes the trend in P/S Ratio of GLENMARK PHARMACEUTICALS over the last five years.

Historical PS (Price/Sales) ratio chart of GLENMARK PHARMACEUTICALS


PS Ratio Performance Analysis for GLENMARK PHARMACEUTICALS

- GLENMARK PHARMACEUTICALS 's latest p/e ratio is 3.10x.

- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 1.24x.

- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 1.13x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2024 at 2.29x.

- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2020 of 0.55x.


How does GLENMARK PHARMACEUTICALS 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Sales (Cr)PS RatioMarket Cap (Cr)
GLENMARK PHARMACEUTICALS 13,128.53.1040,729.9
SUN PHARMACEUTICAL INDUSTRIES LTD51,602.57.94409,818.0
DIVIS LABORATORIES LTD9,078.018.13164,628.0
CIPLA LTD27,547.64.38120,775.0
TORRENT PHARMACEUTICALS LTD11,302.09.71109,758.0
DR REDDYS LABORATORIES LTD32,643.93.12101,791.0
MANKIND PHARMA LTD11,641.09.04105,255.0
ZYDUS LIFESCIENCES LTD22,247.44.0990,963.5
LUPIN LTD22,001.64.3094,611.0
AUROBINDO PHARMA LTD30,921.82.2970,834.6
ABBOTT INDIA LTD6,243.210.3364,488.3

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs GLENMARK PHARMACEUTICALS 's P/S Ratio

Top 10 Industry PeersPS Ratio
Min industry PS 2.29x
Max industry PS 18.13x
Median industry PS 4.38x
Average industry PS 6.95x



You may also like the below Video Courses